Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8393MR)

This product GTTS-WQ8393MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8393MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13491MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ14513MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ4601MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ5557MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ13967MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ15174MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ3778MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ3198MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARENEGYR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW